Sanofi ADS (SNY)
Stock · NASDAQ · Health Care
$44.82as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$43.54
Industry
Biotechnology: Pharmaceutical Preparations
About SNY
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever,…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 74,846
- Website
- www.sanofi.com/
Fundamentals
- 1-day range
- $45.42$46.02
- Market cap
- $104.60B
- P/E (trailing)
- 16.24
- P/E (forward)
- 8.55
- EPS (trailing)
- $4.60
- Dividend yield
- 4.12%
- Beta
- 0.76
- Avg. volume
- 3.40M
- Ex-dividend date
- May 4, 2026
- Dividend pay date
- June 3, 2026
52-week range
$71.25$91.15
Next earnings: October 30, 2026 · EPS estimate $1.54confirmed
Forecasts
9 analyst ratings
Buy 57%
Hold 40%
Sell 3%
1-year price forecast
High
$63
+40.6%
Median
$54.5
+21.6%
Low
$45
+0.4%
Sanofi ADS Competitors
Chosen by industry and closest market cap.
- SNYSanofi ADS$44.82▼ 0.04%Market cap $104.60BP/E 16.24$71.25$91.15
- GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)$50.82▲ 1.09%Market cap $105.65BP/E 15.53$1,441$2,282
- VRTXVertex Pharmaceuticals Incorporated Common Stock$541.72▼ 1.06%Market cap $122.68BP/E 30.70$374.17$555.69
- REGNRegeneron Pharmaceuticals Inc. Common Stock$793.96▼ 1.70%Market cap $79.49BP/E 18.98$541$847
- PFEPfizer Inc. Common Stock$27.95▼ 0.25%Market cap $149.33BP/E 35.19$23.58$28.75
- TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)$18.04▲ 0.06%Market cap $53.78BP/E —$4,102$6,033
- ONCBeOne Medicines Ltd. American Depositary Shares$366.79▼ 1.53%Market cap $36.67BP/E 88.12$205.51$346
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SNY Sanofi ADS | $104.60B | 16.24 | $44.82 | ▼ 0.04% | $71.25$91.15 |
| GSK GSK plc American Depositary Shares (Each representing two Ordinary Shares) | $105.65B | 15.53 | $50.82 | ▲ 1.09% | $1,441$2,282 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $122.68B | 30.70 | $541.72 | ▼ 1.06% | $374.17$555.69 |
| REGN Regeneron Pharmaceuticals Inc. Common Stock | $79.49B | 18.98 | $793.96 | ▼ 1.70% | $541$847 |
| PFE Pfizer Inc. Common Stock | $149.33B | 35.19 | $27.95 | ▼ 0.25% | $23.58$28.75 |
| TAK Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | $53.78B | — | $18.04 | ▲ 0.06% | $4,102$6,033 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $36.67B | 88.12 | $366.79 | ▼ 1.53% | $205.51$346 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavaxbenzinga · 8/27/2026
- TG Therapeutics: Briumvi's Growth Attracts Buyout RumorsSeekingAlpha · 8/22/2026
- European Medicines Agency Concerns Prompt Sanofi To Pull Dupixent IndicationBenzinga · 8/18/2026
- EU EMA Announces Sanofi Winthrop Industrie Withdrew Its Application For The Use Of Dupixent In The Treatment Of Adults With Moderate-To-Severe Bullous Pemphigoid On June 24Benzinga · 8/18/2026
- Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another ComingSeekingAlpha · 8/14/2026
- [Latest] Global Whey Protein Market Size/Share Worth USD 26.04 Billion by 2034 at a 7.56% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)Yahoo · 8/12/2026
- InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001Yahoo · 8/12/2026
- Prime Medicine: An Initial PrognosisSeekingAlpha · 8/11/2026
- A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?Yahoo · 8/11/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 206.95M
- Total value held
- $9.69B
- Institutional holders
- 736
Top holders this quarter
- Unknown29.50M
- Unknown12.51M
- Unknown11.44M
- Unknown9.48M
- Unknown7.17M
- Unknown6.62M
- Unknown5.89M
- Unknown5.04M
- Unknown4.75M
- Unknown4.01M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 30, 2026
SNY: COVID Vaccine Approvals and Vaccine Policy Debate in Focus. The FDA recently approved updated COVID vaccines from Moderna, Pfizer and Novavax, a development relevant to Sanofi's role in the vaccine market and the broader policy conversation around immunizations. Separately, an analyst piece argued that changes in U.S. vaccine policy under the Trump administration are unlikely to disrupt Sanofi's longer-term story. Adding to the policy backdrop, Dr. Oz publicly stated the MMR vaccine is not lethal, as the administration faces questions on vaccine messaging. Together, these items place vaccine regulation and policy back at the center of attention for Sanofi investors.